|
MUC1 & ZAG IHC New Biomarkers for Prostate Cancer Prostate cancer vary in their "aggressiveness", with the Gleason pattern and Gleason score being useful, but imperfect measures of the biology of the cancer. A number of recent publications have documented the prognostic relevance of the expression of two proteins in prostate cancers, MUC1 and ZAG (also known as AZGP). Prostate cancers expressing MUC1 in the absence of ZAG have a much worse prognosis, while those expressing ZAG alone have a good prognosis. Cancers which express both proteins, or lack of expression of both, have an intermediate prognosis (Figure).  TissuPath is now providing two-color MUC1-ZAG immunohistochemical staining of prostate biopsies and radical prostatectomy specimens to assist our client urologists and their patients in determining optimal management strategies. MUC1-ZAG testing can be requested either at the time the specimen is obtained or retrospectively; the results are usually available within 24-48hrs. |
|
Affiliations & Collaborations: Cancer Council Victoria, Victorian Tissue Banking Initiative, RMIT, Monash University, Monash Institute for Medical Research, Burnet Institute for Medical Research & Public Health
